References
- Maloney D G, Grillo-López A J, White C A, Bodkin D, Schilder R J, Neidhart J A, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195
- Wilop S, Galm O, Dada R, Osieka R, Jost E. Rituximab-associated fluctuations in platelet counts: a clinical threat?. Leuk Lymphoma 2008; 49: 2116–2124
- Rigamonti C, Volta C, Colombi S, Forti L, Savinelli F, Gaidano G, Bartoli E. Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion. Leukemia 2001; 15: 186–187
- Rosado M, Chao H, Rose M. Severe acute thrombocytopenia following rituximab therapy. Leuk Lymphoma 2007; 48: 2239–2240
- Otrock Z K, Mahfouz R A, Oghlakian G O, Salem Z M, Bazarbachi A. Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica 2005; 90: e66–e67
- Pamuk G E, Donmez S, Turgut B, Demir M, Vural O. Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia. Am J Hematol 2005; 78: 81
- Shah C, Grethlein S J. Case report of rituximab-induced thrombocytopenia. Am J Hematol 2004; 75: 263
- Farina G, Giordano G, Papini S, Zappacosta B, Storti S. Rituximab induced thrombocytopenia in marginal lymphoma and hairy Cell leukemia: a rare, but possible complication. Report of four cases. Haematologica 2007; 92(53):128